IFNA1 and diffuse large B-cell lymphoma: Suppression of type I interferon by STAT3 has been described in non-GCB DLBCL, with inhibition of STAT3 activity using ruxolitinib inducing a synergistic growth inhibition effect when combined with the IFN-inducing immunomodulatory drug lenalidomide (147).